CHEK:NSC-Check-Cap Ltd.

EQUITY | Medical Diagnostics & Research | NASDAQ Capital Market

Last Closing Price

USD 0.98

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

3.09M

Yahoo Analyst Target

USD 4.13 (323.07%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Check-Cap Ltd is a clinical stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-15 )

Largest Industry Peers for Medical Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc.

N/A

USD 15.11B
EXAS Exact Sciences Corporation

N/A

USD 6.30B
ICLR ICON plc

N/A

USD 6.13B
PRAH PRA Health Sciences Inc.

N/A

USD 5.71B
BRKR Bruker Corporation

N/A

USD 5.44B
DXCM DexCom Inc.

N/A

USD 4.93B
PRXL PAREXEL International Corporat..

N/A

USD 4.50B
SYNH Syneos Health Inc.

N/A

USD 4.27B
INCR INC Research Holdings Inc.

N/A

USD 4.23B
NEOG Neogen Corporation

N/A

USD 3.05B

ETFs Containing CHEK

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Diagnostics & Research)
Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.23% 84% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.23% 84% B 87% B+
Trailing 12 Months  
Capital Gain -58.10% 18% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.10% 18% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.34% 29% F 12% F
Dividend Return -13.34% 29% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.21% 65% D 49% F
Risk Adjusted Return -47.28% 20% F 11% F
Market Capitalization 0.03B 16% F 8% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Diagnostics & Research)
Ratio vs. Market
(NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -0.76 50% F 59% F
Price/Book Ratio 2.17 78% C+ 51% F
Price / Cash Flow Ratio -0.46 67% D+ 72% C-
Price/Free Cash Flow Ratio -1.74 59% F 62% D-
Management Effectiveness  
Return on Equity -259.53% 17% F 4% F
Return on Invested Capital -263.75% 12% F 2% F
Return on Assets -202.56% 9% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector